1. The role of corticosteroids in the current treatment paradigm for myelofibrosis.
- Author
-
Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Rossi, Teresa, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo
- Subjects
CORTICOSTEROIDS ,MYELOFIBROSIS ,BONE marrow ,THERAPEUTICS ,IMMUNOREGULATION ,CYTOKINES - Abstract
Introduction: Myelofibrosis (MF) is a clonal hematological disorder characterized by bone marrow fibrosis, splenomegaly, and inflammatory cytokine dysregulation. While the role of steroids in MF is not fully defined, their anti-inflammatory properties may offer therapeutic benefits, particularly in managing anemia and other cytopenias. Steroids exert their effects by suppressing pro-inflammatory cytokines such as IL1, IL6, and TNF, and by enhancing anti-inflammatory cytokines like IL4 and IL10. Elevated levels of IL6 and other cytokines in MF are associated with anemia and poor prognosis, suggesting that steroid therapy could mitigate these effects. Areas covered: In this manuscript, we review clinical studies which evaluated the safety and efficacy of steroids in MF patients. Moreover, we examine clinical data of the combination of steroids with immunomodulatory agents and JAK inhibitors. Our literature search consisted of an extensive review of PubMed and clinicaltrials.gov. Expert opinion: The role of steroids in the management of MF remains poorly defined, though emerging evidence suggests a potential therapeutic benefit, particularly in managing anemia and other cytopenias. The combination with IMIDs has also yielded positive outcomes as demonstrated in several studies. Steroids may also play a crucial role in managing cytopenias in MF patients receiving JAKi. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF